Podcasts about breakthroughs

Host Piya Chattopadhyay speaks with The Atlantic's Toluse "Tolu" Olorunnipa and Politico's Hailey Fuchs about the revelations in Friday's partial release of the Epstein files – and how they intersect with U.S. politics, baker and writer Ruby Tandoh explains how virality shapes our appetites, Dr. Siddhartha Mukherjee discusses breakthroughs in cancer research, and novelist Gary Shteyngart explores the parallels between his dystopian new novel and life in the U.S. today.

In this episode of The AI Report, your always-on AI anchors Artie Intel and Micheline Learning break down December 2025’s wildest developments in artificial intelligence, from the latest “singularity-speed” model launches to the hot new tools quietly rewiring how humans work, create, and build businesses. They unpack the new generation of frontier models such as Claude Opus 4.5, Gemini 3, and GPT‑5.2, and explain why everyone from solo creators to Fortune 500 companies is racing to plug them into real workflows rather than just playing with demos.​ You’ll hear how AI is now helping inspect semiconductor chips with near‑perfect accuracy, acting as an autonomous “AI scientist” to hunt for discoveries, and even critiquing its own math proofs so humans can trust the numbers. The show also tours the month’s hottest tools: Runway Gen‑4 Turbo for video, Notion AI 3.0 for workspace automation, Adobe Firefly 4 for image generation, and advanced coding copilots and observability platforms that are changing how software gets shipped.​ Artie and Micheline zoom out to tackle the significant tensions of 2025’s “AI hype correction”: running out of quality training data, the rise of synthetic data, and the gap between shiny pilots and real productivity gains in the AI economy. They examine how governments are responding, with significant investments such as the U.S. Department of Energy’s Genesis Mission for AI‑powered science, and what it all means for workers, creators, and decision‑makers trying to stay ahead of the algorithm.​ If you want one tight, fast‑moving briefing that covers model wars, new tools, scientific breakthroughs, and the real risks behind the headlines, this is your must‑hear download on the state of AI at the end of 2025.​ Sponsor: This episode of The AI Report is brought to you by Amazon.com, your always‑open destination for last‑minute gifts, from smart gadgets to everyday essentials, delivered at the speed of your next great idea.  

Strategy founder and executive chairman Michael Saylor named one of CoinDesk's 50 Most Influential. Strategy founder and executive chairman Michael Saylor was named one of CoinDesk's 50 Most Influential people of 2025. He reflects on the evolution of bitcoin treasuries, from a niche corporate experiment into a global phenomenon, detailing how Strategy has moved beyond simple accumulation into a high-growth operating business centered on digital credit. Plus, his bullish case for bitcoin's growth and outlook into the asset's volatility. – For more, check out CoinDesk's 50 Most Influential article on Michael Saylor: https://www.coindesk.com/business/2025/12/12/most-influential-michael-saylor.  To see the full list, visit: ⁠https://www.coindesk.com/most-influential-2025⁠.  – Timecodes:  01:21 Michael Saylor's Bitcoin Journey 02:52 Institutional Support and Bitcoin Volatility 04:18 Bitcoin Treasury Strategies and Digital Credit 06:03 Exploring Digital Credit and Its Practicality 11:49 The Future of Bitcoin Treasury Companies 12:42 Innovations in Digital Credit Instruments 27:08 Challenges and Breakthroughs in 2025 39:16 Looking Ahead: Bitcoin's Price and Market Structure Legislation 43:29 Top Digital Assets for 2026 - Break the cycle of exploitation. Break down the barriers to truth. Break into the next generation of privacy. Break Free. Free to scroll without being monetized. Free from censorship. Freedom without fear. We deserve more when it comes to privacy. Experience the next generation of blockchain that is private and inclusive by design. Break free with Midnight, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠midnight.network/break-free⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - This episode was hosted by Jennifer Sanasie.

The 2025 NAIA Cross Country National Championships are in the books — and we're breaking it all down with the coaches who lived it.Originally streamed LIVE on YouTube on November 24, 2025, this episode is now available on all Airey Bros Radio podcast platforms as Episode 421.Recorded just days after the championship meet at Apalachee Regional Park in Tallahassee, Florida, the Airey Bros are joined by five elite NAIA head coaches to unpack team titles, podium finishes, All-American performances, heartbreak by a single point, and the moments you don't see on the results sheet.

Spiritual awakening in 2025 is changing fast. In this video, I share the top 5 spiritual lessons of 2025, including how AI can weaken intuition, why nervous system healing is essential for spiritual growth, and what it really means to trust your inner guidance during awakening.If you're experiencing a spiritual awakening, developing your intuition, or feeling overwhelmed by information, technology, or AI tools, these lessons will help you reconnect to your inner knowing in a grounded, embodied way.Sharing my top 5 Reality Check Breakthroughs I had this year. In 2025, my spiritual growth changed in ways I didn't expect... This year taught me that spiritual growth isn't linear — it's a spiral, intuition isn't something you “optimize,” and that over-reliance on AI and external guidance can quietly disconnect us from our inner knowing.In this video, I share the top 5 spiritual lessons I learned in 2025, including how intuition develops through nervous system regulation, why growth often reveals itself in strange ways, and how learning to feel safe with uncertainty is essential for spiritual awakening (and the collective chaos happening all around us) This isn't about rejecting technology — it's about discernment, embodiment, and reclaiming intuitive authority in a world that constantly pulls us outward.Lets be clear i'm not anti-AI but I SURE think it's doing something bts to our intuition if we're not careful and it's DESTROYING FREE THINKING. Let's talk about it.✨ In this video, you'll learn:Why spiritual growth happens in spirals, not straight linesHow intuition acts as your guiding post during awakeningThe hidden ways AI can suppress free thinking and intuition when used as a crutchWhy nervous system healing is foundational for intuitive developmentHow to feel safe walking with uncertainty instead of forcing answersIf you're navigating a spiritual awakening, emotional healing, intuition development, or feeling overwhelmed by information overload, this episode is for you.Before you go don't forget:

Aviation Week's James Pozzi, Lee Ann Shay, Lindsay Bjerregaard and Sean Broderick look back at 2025 and reflect on the biggest stories and breakthroughs in the MRO world. Is Parts Integrity Finally Having Its Moment? Supply Chain Integrity Coalition Shifts Gears  Rolls-Royce Unveils China MRO Joint Venture How Stability, Slots And Strategy Are Reshaping Base Maintenance Schools Say FAA Testing Hurdles Are Stifling MRO Workforce Growth

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements, revealing a landscape rich with scientific innovation and strategic maneuvers poised to impact patient care and the drug development pipeline.Let's start with Johnson & Johnson's recent FDA approval for a subcutaneous version of Rybrevant, their lung cancer medication. This new formulation offers a more convenient administration method compared to AstraZeneca's Tagrisso, intensifying competition in the non-small cell lung cancer market. The shift towards more patient-friendly delivery systems underscores the industry's commitment to enhancing treatment adherence and convenience. In contrast, Insmed faced a setback with its phase 2 trial for Brinsupri in treating chronic rhinosinusitis without nasal polyps. The discontinuation of this program highlights the unpredictable nature of clinical trials and emphasizes the need for rigorous scientific validation before advancing therapeutic candidates.Meanwhile, Lilly has shown promising results with its oral obesity pill, marking significant progress in weight management therapies. Patients transitioning from injectable GLP-1 therapies to Lilly's oral drug candidate maintained substantial weight loss, positioning Lilly favorably against Novo Nordisk's Wegovy. The potential for oral formulations to revolutionize treatment paradigms in chronic conditions cannot be understated. Lilly's progress in obesity treatment with its oral medication orforglipron further cements its competitive edge. Participants in their Phase III clinical trial maintained weight loss after switching from Wegovy or Zepbound to orforglipron, suggesting an efficacious oral alternative to injectable treatments and potentially enhancing patient adherence.On the regulatory front, the Biosecure Act's progression within a major defense spending bill could impose new challenges for life sciences companies with Chinese affiliations. This legislative shift reflects geopolitical tensions impacting global pharmaceutical collaborations and underscores the importance of regulatory compliance in international partnerships. Similarly, Intercept Pharmaceuticals' restructuring following the withdrawal of Ocaliva from the U.S. market is indicative of strategic pivots in response to regulatory hurdles and evolving market dynamics.In dermatology, Takeda's successful phase 3 trials for Zasocitinib highlight the competitive nature of drug development as multiple players vie for market share within therapeutic areas. Their anticipated 2026 FDA filing underscores the prolonged timelines involved in bringing novel therapies to market despite successful clinical outcomes.Public-private collaborations continue to play a crucial role in vaccine development, as evidenced by Moderna's pandemic influenza vaccine advancement into phase 3 trials with support from the Coalition for Epidemic Preparedness Innovations (CEPI). This $54 million investment illustrates ongoing efforts to bolster pandemic preparedness through innovative mRNA technologies. Meanwhile, Moderna's $54 million funding from CEPI to advance its bird flu vaccine highlights resilience amidst fluctuating governmental support. This endeavor leverages Moderna's mRNA technology platform, emphasizing mRNA's versatility across various infectious diseases.Shifting our focus slightly, medical groups have expressed opposition to changes in hepatitis B vaccination recommendations by the CDC for newborns. Such policy debates have significant implications for public health strategies and highlight ongoing discussions within medical communities regarding optimal vaccination protocols.GSK's strategic collaboration with Camp4 Therapeutics marks another key industry development. With an investment exceeding $400 million, GSK aims to Support the show

Welcome to our final episode for 2025. We're taking a little break for the holidays but we'll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA's M Ventures, Hakan Goker.Today, though, I'm joined by Ester in t'Groen of Johnson & Johnson.Fresh off the American Society of Hematology (ASH) Annual Meeting in Orlando, where J&J presented over 60 abstracts, Ester shares insights into the company's portfolio and the advances that the company has made over recent years in the hematology space.She walks us through the real-world evidence for some pretty significant results from the thousands of patients in their clinical trials, and explain what's next for J&J in hematology in 2026—including some exciting readouts.01:14 - Meet Ester in t'Groen    02:37 - Winning the Kilmer Medal06:32 - J&J's key focus areas07:32 - The hematology portfolio19:07 - All about ASH 202523:49 - The MajesTEC-3 data27:43 - The value of real-world datasets32:06 - Looking forward into 2026Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Blood Cancer Awareness Month: What biotech holds in store 10 oncology deals in 2025 spotlight where industry leaders are betting bigT cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

In this episode of The Brainy Business podcast, Melina Palmer speaks with Muriel Wilkins, author of Leadership Unblocked: The Beliefs That Limit Your Potential. Together, they delve into the often-hidden beliefs that can hinder effective leadership and personal growth. Muriel, an executive coach with over 20 years of experience, shares insights from her extensive work with C-suite leaders, revealing seven common beliefs that can create barriers to success. The conversation explores how these beliefs—such as "I need to be involved" and "I can't make a mistake"—shape our behaviors and decision-making processes. Muriel emphasizes the importance of self-awareness and shifting mindset to overcome these challenges, encouraging listeners to reflect on their own assumptions and the narratives they tell themselves. As you tune in, think about which beliefs may be holding you back and how you can reclaim your agency as a leader. In this episode: Discover the seven hidden beliefs that can limit leadership potential. Learn how to recognize the narratives that shape your experiences. Explore practical strategies for shifting mindset and overcoming barriers. Gain insights into the importance of external feedback and self-reflection. Understand how to take actionable steps toward personal and professional growth. Get important links, top recommended books and episodes, and a full transcript at thebrainybusiness.com/556. Looking to explore applications of behavioral economics further?  Learn With Us on our website. Subscribe to Melina's Newsletter, Brainy Bites.  Let's connect: Send Us a Message Follow Melina on LinkedIn The Brainy Business on YouTube The Brainy Business on Instagram

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent news updates and key advancements shaping the industry in 2025.Staying healthy during the holidays (00:18): Discover how to protect yourself and others as a new influenza strain, holiday gatherings, and increased travel raise the risk of spreading viruses. 2025 breakthroughs and trends (04:31): Learn more about the technologies, regulations, and innovation influencing the future of clinical diagnostics. Note: Information in this post was accurate at the time of its posting.Resources"Answers From the Lab” podcast: Innovations Set to Shape the Industry in 2025Dr. Morice shares trends and predictions for 2025Mayo Clinic Minute: How to prepare for the influenza seasonMayo Clinic Minute: Wash your hands for better healthVaccines and viruses: Protecting health across generations

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we close out the year 2025, it's clear that the pharmaceutical and biotech industries have experienced a period of significant transformation. This year has been marked by groundbreaking drug approvals, strategic partnerships, and a focus on innovative therapies that promise to redefine patient care.One of the standout achievements this year comes from GlaxoSmithKline, which received approval from the U.S. FDA for its ultra-long-acting biologic, Exdensur, aimed at treating severe asthma with an eosinophilic phenotype in adolescents and adults. This approval underscores the growing trend toward personalized medicine and biologics, offering new hope for patients with chronic respiratory conditions by providing more sustainable and personalized treatment options.In the oncology sector, Merck's Keytruda and Astellas Pharma's Padcev have demonstrated significant overall survival benefits when used as perioperative treatments for cisplatin-eligible muscle-invasive bladder cancer. This combination therapy of a PD-1 checkpoint inhibitor and an antibody-drug conjugate highlights the evolving landscape of cancer treatment, emphasizing the role of immunotherapy and targeted therapies in improving patient outcomes in challenging cancer subtypes.However, not all developments have been positive. Hansa Biopharma faced challenges with its kidney transplant drug, imlifidase. Despite success in kidney transplant trials, it failed to achieve desired results in treating anti-glomerular basement membrane disease. This serves as a reminder of the complexities involved in drug repurposing efforts within autoimmune diseases.Alnylam Pharmaceuticals announced a significant investment to enhance its Norton, Massachusetts facility into a dedicated site for small interfering RNA (siRNA) production. This move reflects the industry's shift towards RNA-based therapies that offer targeted gene-silencing capabilities and positions Alnylam at the forefront of RNAi therapeutics production.In another promising development, ImmunityBio reported positive data from its QUILT-3.032 study on Anktiva for BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary disease. The potential expansion of Anktiva's use reinforces the importance of personalized immunotherapies in oncology.The launch of Ambros Therapeutics with $125 million in Series A funding highlights efforts to develop non-opioid pain medications already approved abroad. This initiative addresses chronic pain management without relying on opioids, potentially advancing analgesic therapies amidst the ongoing opioid crisis.In China, Fosun Pharma's acquisition of a majority stake in Green Valley Pharmaceuticals aims to revive a controversial seaweed-derived Alzheimer's medication. Despite skepticism over its efficacy, this investment signals continued innovation efforts amid growing demand for effective Alzheimer's treatments.Siemens Healthineers' partnership with Alzpath to incorporate pTau-217 antibodies into its Atellica immunoassay platforms marks a significant step forward in Alzheimer's diagnostics. This collaboration aims to enhance biomarker detection capabilities crucial for early diagnosis and intervention strategies in neurodegenerative diseases.On the strategic front, Bristol Myers Squibb entered into a substantial research agreement with Harbour BioMed valued at up to $1.1 billion. This deal underscores Big Pharma's ongoing pursuit of alliances to advance therapeutic pipelines and antibody technologies.Finally, Cencora's acquisition of OneOncology for $5 billion underscores consolidation trends within specialty practice networks. By valuing OneOncology at $7.4 billion, this acquisition reflects the growing importance of integrated oncology care models and collaborative netSupport the show

What if the hardest seasons in your business turned out to be the ones that set you free?  In this deeply honest episode, Marina Gregor, one of our senior business coaches sits down with Andrew Graham, a cattle producer from southwest Victoria, to explore a powerful story of resilience, family, and business transformation.  Andrew was previously burnt out, juggling operations management for a large-scale dairy business while navigating succession plans for his own family farm. Fast forward to today, and his world looks remarkably different, with a thriving cattle operation with 2,500 head, family back on the land, systems in place, and a sense of balance he never thought possible.  This episode is a conversation about what happens when you step out of survival mode and into leadership with clarity and intention. It's about letting go, backing yourself, and creating a business that truly works for you.  Together, they explore:  The messy reality of succession and how Andrew found clarity through it  How burnout showed up, and what it took to finally slow down  Why mindset, not just management, was the missing piece  What changed when Andrew started building the business around his life  The power of building a team and trusting them to lead  These small shifts might not look like much at first, but they're where real change starts. On the farm, it's the everyday choices including how you plan, how you work with others and how you set priorities that determine the outcome of the season. The same applies in leadership. Creating space to step back, adding structure to the work, trusting others to lead, and getting clear on roles and direction helped Andrew move from burnout to focus and confidence.  If you're looking to do the same, now is the time to take stock. Block time early in the new year to step off-farm and get clear on your 12-month priorities, because without space, clarity rarely comes. Need help resetting your goals for the new year ahead? Our Ultimate 2026 Planning Guide can help. It's a practical resource designed to support reflection, bring focus, and give you a framework to set clear, purposeful goals for the year ahead. Download the guide here.  Thank you Andrew for your openness, your wisdom, and your leadership. You've not only changed your business, you're lighting the way for others too. And to Marina, thank you for stepping in to lead this conversation with insight and care. Your ability to support others to reflect, share honestly, and draw out lessons that others can learn from is what makes conversations like this truly valuable.  Sincerely,   Jeremy Hutchings and the Farm Owners Academy Team 

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Advances in AI are transforming both large-scale population analytics and ultra-precise, small-data insights that can guide individualized treatment. In this episode, Yves Lussier, Chair of Biomedical Informatics and Professor of Medicine, discusses the deep legacy of innovation behind modern electronic health records, the evolution of biomedical informatics, and the rise of AI techniques that extract meaning from both massive and minimal datasets. He explains how the “blessing of dimensionality” enables N-of-1 precision genomics, why counterfactual data and adversarial risks matter for large language models, and how engineered negative datasets could strengthen future AI systems. He also reflects on his entrepreneurial journey, from pioneering pen-based AI medical records in 1991 to building clinical data warehouses and founding major bioinformatics programs. Yves shares lessons on risk, career leaps, and the cultural ecosystems that fuel innovation.  Tune in and learn how cutting-edge informatics is reshaping research, care, and the future of AI-driven medicine! Resources: Connect with and follow Yves Lussier on LinkedIn. Follow the University of Utah School of Medicine on LinkedIn and visit their website!

Breakthroughs may look sudden, but nothing in God's kingdom happens by accident

Dr. Tina Kaczor and Dr. Leah Sherman discuss new diagnostic tools that can tell benign tumors from cancer in the pancreas, highlight the growing concerns over microplastics, and explore the link between ultra-processed foods and early colorectal cancer. They also highlight some amazing inventions by teenagers, like a melanoma-detection app and a skin-cancer-reducing soap. Last, they cover the benefits of hypnosis before breast cancer surgery and the health impact of commonly used chemicals in dry cleaning. This episode provides valuable insights for anyone interested in cancer prevention, early diagnosis, and overall wellness.Soap for skin cancers invented by TIME's Kid of the Year, Hemen BekeleA skin cancer detecting app invented by Richmond, VA high-schoolersThe dramatic increase in glyphosate use across the Midwest in the USAThe rising rates of cancer in young people around the worldExposure of rat fetuses to glyphosate levels led to early cancer developmentThe rising rate of glyphosate exposure over time Support the showBecome a member of The Cancer Pod Community! Gain access to live Q&As, exclusive content, and so much more! Join us today! Check out our website! Looking for more information? We have blogs, merch, and all of our episodes listed by season and category. Shop our favorite reads! We've joined with Bookshop.org to offer some of our fave books! Have a comment or suggestion? Email us at thecancerpod@gmail.com Follow us wherever you browse. We're always @TheCancerPod: Instagram Bluesky Facebook LinkedIn YouTube THANK YOU!!

Synopsis: This episode is proudly sponsored by Quartzy. Roivant Sciences CEO Matt Gline returns to Biotech 2050 for a deeply reflective conversation with host Rahul Chaturvedi on what it really takes to build a biotech company that lasts. From Roivant's transformational $7B Pfizer-to-Roche deal to delivering registrational Phase 3 data in dermatomyositis—one of biotech's most difficult graveyard indications—Matt shares how disciplined execution, decentralization, and learning from failure shaped Roivant's trajectory. The discussion explores Roivant's unique “Vant” model, why multiple CEOs can outperform centralized command-and-control structures, and how thoughtful clinical trial design—down to steroid tapering and site execution—can make or break outcomes in rare disease development. Beyond science and strategy, Matt reflects candidly on his own evolution as CEO, the realities of leading a public biotech through volatile markets, and why authenticity, focus, and embracing hard lessons matter more than chasing hype. This episode is a masterclass in biotech leadership, clinical development, and long-term value creation. Biography: Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Earlier this year, The Michael J. Fox Foundation hosted its 2025 Research Roundtable, “Building on Breakthroughs.” Tune into audio from this event to hear Parkinson's experts and MJFF staff discuss the latest in lifestyle medicine and treatments in the pipeline, as well as the power of advocating for Parkinson's policy.Like our podcasts? Please consider leaving a rating or review and sharing the series with your community. https://apple.co/3p02Jw0Whether you have Parkinson's or not, you can help move research forward. Join the study that's changing everything at michaeljfox.org/podcast-ppmiMentioned in this episode:Research will move us closer to a cure for Parkinson's — but we can't do it without you. Help us accelerate more life-changing breakthroughs by visiting michaeljfox.org/givetoresearch to donate today.

As we close out 2025, this episode of Pivot The Path is all about reflection, clarity, and momentum.In Episode 105, we recap the five biggest golf improvement lessons from the past year — what actually helped golfers play better, move better, and think smarter on the course. From understanding movement and managing the golf IQ side of the game to building trust and consistency, these are the takeaways that truly moved the needle in 2025.These are the lessons that helped golfers take ownership of their improvement — to truly Own Your SSWING — and carry that momentum into 2026.We also dive into what pivoting meant this year — how shifts in approach, coaching, and mindset shaped both our own games and the evolution of SSWING — and what those pivots tell us about where golf improvement is headed in 2026.To wrap things up, we share a look at what's next for Pivot The Path and SSWING in the year ahead, express gratitude for an incredible community of listeners and guests, and finish with simple, practical holiday stretches you can use to stay loose, mobile, and ready — even during travel, downtime, and cold weather — so you can head into the holidays moving well and feeling ready.Thank you for being here. Let's keep learning together and enjoying this incredible game we love.Shop SSWING Swag

2025 was a year of seismic shifts in tech, as AI surged into a critical growth phase with massive investments, partnerships, and global trade battles over chips. Intel and HPE restructured for the AI era, quantum computing made strides with Microsoft, Google, and Cisco advancing real-world applications, and cloud giants struck multibillion-dollar deals. Meanwhile, strategic acquisitions reshaped the landscape—Lenovo, SoftBank, Google, Qualcomm, Anthropic, and more strengthened AI, cloud, cybersecurity, and quantum capabilities—highlighting a year defined by scale, innovation, and high-stakes competition across the technology ecosystem.Time Stamps0:00 - Cold Open0:17 - Welcome to the Tech Field Day News Rundown 1:09 - AI is at an Inflection Point, Who Really Controls its Future?4:58 - Intel at a Crossroads: Layoffs, Leadership Change, and the Fight to Stay Relevant in AI9:31 - The Internet Is More Fragile Than You Think14:33 - HPE Under Pressure and on the Move20:39 - The Global AI Trade War Heats Up27:10 - Quantum Computing Is Moving From Hype to High Stakes30:55 - Cloud Wars Heat Up as Tech Giants Expand AI Infrastructure33:33 - Billion-Dollar Deals Changing and Redefining the Future of AI and Cloud37:53 - Upcoming Tech Field Day Events in 202643:30 - Thank You to our Guest Cohosts in 202545:27 - Thanks for Watching the Tech Field Day News RundownFollow our hosts ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Tom Hollingsworth⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Alastair Cooke⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Stephen Foskett⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow Tech Field Day ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠on LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠X/Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bluesky⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Mastodon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

A couple of years ago, Gavin became frustrated with science journalism. No one was pulling together results across fields; the articles usually didn't link to the original source; they didn't use probabilities (or even report the sample size); they were usually credulous about preliminary findings (“...which species was it tested on?”); and they essentially never gave any sense of the magnitude or the baselines (“how much better is this treatment than the previous best?”). Speculative results were covered with the same credence as solid proofs. And highly technical fields like mathematics were rarely covered at all, regardless of their practical or intellectual importance. So he had a go at doing it himself. This year, with Renaissance Philanthropy, we did something more systematic. So, how did the world change this year? What happened in each science? Which results are speculative and which are solid? Which are the biggest, if true? Our collection of 201 results is here. You can filter them by field, by our best guess of the probability that they generalise, and by their impact if they do. We also include bad news (in red). Who are we? Just three people but we cover a few fields. [...] ---Outline:(01:24) Who are we?(01:54) Data fields --- First published: December 16th, 2025 Source: https://www.lesswrong.com/posts/5PC736DfA7ipvap4H/scientific-breakthroughs-of-the-year --- Narrated by TYPE III AUDIO.

What happens when four hard-charging leaders shut the door, turn on the mics, and tell the unfiltered truth about business, burnout, delegation, AI, hiring, and scaling? You get one of the rawest, most practical leadership episodes we've ever released. Host Sean Meyers is joined by the Level Up + Live leadership team, Cody Schneider, Micah Harhoff, and Michael David Riley (MD), for a no-fluff, high-impact roundtable Q&A straight from our members. They tackle the REAL questions every entrepreneur is scared to ask: The first bottleneck that forced them to stop working in the business and start working on it How they're using AI without killing culture or trust When to hire (even when you “can't afford it”) How much to REALLY spend on marketing The biggest mistakes owners make when scaling too fast… or too slow Why burnout, ego, and control quietly destroy businesses The truth about proving people wrong vs. finding real purpose You'll hear real stories about missed family moments, burnout, failed businesses, delegation struggles, buy-back-your-time strategies, leadership growth, and the systems that separate hustlers from true builders. This is not a theory. This is battle-tested leadership from the trenches. And just when the conversation hits full stride… they drop a cliffhanger and announce Part 2 is coming. If you're an entrepreneur, emerging leader, or business owner who's serious about building something that lasts, this episode will hit different. Press play. Take notes. Level Up. Live better. Ready to Level Up Your Life and Business? Join our Level Up + Live Mastermind, the weekly power room for business owners and leaders hungry for clarity, accountability, and growth without sacrificing their soul in the process. Try it FREE for one month, levelupandlive.com/contact Hit play. Get uncomfortable. Live with intention. Stay in the loop; stay in the lead! Get exclusive insights on business, fitness, leadership, and community straight to your inbox! Subscribe to the Level Up + Live newsletter now Level Up + Live  Tools to Level Up! Free Resources — Level Up + Live

In this episode, Jenn Cody sits down with Jess Tergesen, the Director of Education at Strategies, for a heartfelt conversation about leadership, empowerment, and the future of beauty business education. Jess shares her unexpected journey from reluctant cosmetology student to industry leader, her 11-year tenure at a values-based team company, and her vision for transforming how beauty professionals learn and grow.Whether you're a salon owner looking to build a stronger team culture or a stylist wanting to step into leadership, this episode delivers powerful insights on creating businesses where everyone thrives.Key Topics CoveredFrom Behind the Chair to Director of Education: Jess's unconventional path into the beauty industry and why she stayed at one company for 11 yearsValues-Based Business Culture: What it really means to lead with values and how it shapes team loyalty and retentionLeadership Is Not a Title: Why everyone in your business can (and should) be a leader, regardless of their roleEmpowerment Through Self-Trust: Jess's personal definition of empowerment and the growth cycle every leader experiencesThe Future of Strategies Education: A complete breakdown of N.E.X.T. Austin 2026 and the new CoLab class formatTeam + Owner Collaboration: How shared language around numbers, leadership, and culture creates transformationFelt Experiences vs. Taught Information: Why education should be experienced, not just absorbedEpisode HighlightsOn Choosing Hair School: "I had my daughter when I was in high school and I was like, what am I going to do with my life to quickly get a job, be independent? I'm super creative and I like to talk to people. So I thought, I could be a hairstylist."On Leadership Being a Behavior, Not a Title: "Leadership is not a title. Anybody can be a leader no matter what their tenure is, no matter how long they've worked there. I believe that people can lead at each and every level."On Her Definition of Empowerment: "Empowerment comes from within. It means learning to trust yourself as a leader. It starts with humility, saying 'I don't know everything and I am willing to learn.'"On Building Shared Language: "When you're anchored in your values, when everybody knows why you're doing what you're doing, it becomes easier to coach to the behaviors that are required to hit the goals."On the New CoLab Education Format: "CoLab stands for collaborate and L.A.B. stands for Leadership, Action, and Breakthroughs. I wanted collaboration between owners and team members, and collaboration between diverse topics."What's Coming in 2026: N.E.X.T. AustinStrategies is launching a reimagined education experience March 2-4, 2026 in AuTo learn more about how Strategies can help you create more profit, fun, and growth potential for you, your business, and your team, schedule a free 60-minute strategy session: Strategies: https://www.strategies.comSalon/Spa Business Coaching: https://strategies.com/memberships/In-Person Salon/Spa Seminars: https://strategies.com/educationPodcast: https://strategies.com/podcast/Instagram: https://www.instagram.com/strategiesteam Facebook: https://www.facebook.com/strategiesOnline Education Portal: https://learning.strategies.com/The Beauty Business Strategies Podcast is designed to give salon, spa, medspa, barbershop, and lash studio owners, just like you, quick tips to make more money, inspire your team, and create world-class client experiences.

Social Media⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Say hi on TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Say Hi on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email List⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----If you've been stuck, doubting your worth, or drowning in regret — this episode is your wake-up call. Henry Lawrence drops a fire-filled reminder that you are not your past. You're not the failures, the shame, or the missed chances. You are potential in motion.In this soul-shifting transmission from The Positive Mindset Podcast, you'll learn:How to break free from your history and step into your powerWhy one moment of clarity can define your legacyThe spiritual truth about pressure, transformation, and becoming the diamondA guided breathwork session to lock in your highest visionThe deeper reason you're still here — and why it's not too lateClose your eyes. Breathe in. See your future self.This is the day everything shifts.

One Big Question Podcast I "“From Bandages to Breakthroughs: The Evolution of Wound Care"From bandages and guesswork to biotech, smart dressings, and data-driven healing — wound care has officially entered its innovation era.From Bandages to Breakthroughs isn't just a timeline, it's a testament to what happens when science, compassion, and technology stop playing small. We've moved beyond treating wounds to understanding healing at the cellular level — faster recoveries, better outcomes, and dignity for patients who deserve more than “good enough.”Progress didn't happen overnight. It happened because clinicians questioned old methods, researchers pushed limits, and innovators refused to accept stagnation. The future of wound care? Smarter, more personalized, and built to heal people, not just injuries.#FromBandagesToBreakthroughs #WoundCareInnovation #FutureOfHealthcare #MedicalAdvancement #HealthTech #ClinicalExcellence #HealingScience #InnovationInMedicine #NextGenHealthcare #MedTechMovement

Marc Kramer, host of the award winning The Best Business Minds, interviews Paul Sloane author of "The Art of Unexpected Solutions: Using Lateral Thinking to Find Breakthroughs"

This episode of The AI Report dives into a wild, high‑stakes week in artificial intelligence, as told by your favorite synthetic anchors, Artie Intel and Micheline Learning. From Hollywood power plays to life‑saving lab breakthroughs, the future is arriving fast, and it brought receipts. Artie and Micheline kick things off in Tinseltown, where Disney throws down a billion‑dollar AI deal with OpenAI while blasting Google over alleged copyright abuses, reshaping the rules of who gets paid when AI learns from blockbuster IP. Then they shift to Washington, D.C., breaking down President Trump’s new executive order to centralize AI regulation at the federal level, explaining why Big Tech is cheering, civil‑rights advocates are nervous, and what a “single national AI rulebook” means for startups, states, and ordinary users.​ From there, The AI Report races through the hottest new AI tools transforming business, marketing, and creative work, from always‑on email and calendar agents to video, design, and avatar platforms that let tiny teams operate like global studios. In the “wow” segment, they spotlight jaw‑dropping breakthroughs: AI‑enhanced medical imaging that spots deadly problems earlier, chip‑inspection systems that catch microscopic defects, wearable brain–computer interfaces empowering paralyzed users, and sketch‑to‑3D agents that turn simple drawings into full models.​ Whether you’re a creator, founder, policymaker, or just trying to keep up with the robots, this episode gives you the stories, stakes, and context behind the headlines, without the hype, and with just enough attitude to keep it fun.

The final Fed meeting of 2025 delivered a surprise rate cut, but the real story is how the market is reacting. In this week's Weekly Rollup, Ryan and David unpack what the new policy shift means for crypto liquidity, why regulators across the SEC, CFTC, and OCC are suddenly embracing onchain markets, and how Tom Lee's massive ETH accumulation is reshaping sentiment. We also get into Ethereum's growing momentum from ZK advancements and blob upgrades, the ZKsync Atlas rollout, Base's bridge drama with Solana, and Farcaster's pivot away from social. Plus, the rise of tokenization, new prediction market rails, and whether this week marks the first real cycle turn for Ethereum. ------

What does it take to build something genuinely new inside a $60B Enterprise? In this podcast hosted by Sid Shaik, Outshift by Cisco VP & CPO Papi Menon breaks down how product leaders can drive meaningful innovation inside massive enterprises, and why the future depends on incubating bold bets like agentic AI and quantum networking. He shares how to identify ideas worth pursuing, how to navigate internal pressure from sales and the board, and how to create strategic optionality that reshapes a company's trajectory. This is essential listening for product leaders looking to understand what high-stakes innovation actually demands.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a myriad of transformative advancements and strategic shifts within these industries, illustrating the profound impact of innovation and regulatory changes on healthcare.Eli Lilly's recent strides in obesity treatment highlight a significant scientific breakthrough with their novel drug, retatrutide. Currently in phase 3 trials, this triple agonist targets GLP-1, GIP, and glucagon receptors, achieving an extraordinary 28.7% weight loss in participants. Additionally, it demonstrated a 75.8% reduction in knee osteoarthritis pain. Yet, the journey to this milestone wasn't without challenges. The trials saw a higher discontinuation rate than earlier studies, reminding us of the delicate balance between efficacy and patient tolerability—a consistent theme in obesity pharmacotherapy as developers strive to maximize benefits while minimizing adverse effects.In a testament to the global nature of drug development, Zealand Pharma has embarked on a $2.5 billion collaboration with a burgeoning Chinese biotech firm. This partnership aims to advance oral cardiometabolic therapies, underscoring the crucial role of strategic alliances in accessing innovative scientific platforms and expanding market reach.Rezolute faced a significant setback with a disappointing phase 3 trial for its hypoglycemia treatment, resulting in an 87% drop in stock value. This starkly illustrates biotech's inherent volatility and the critical importance of robust clinical trial design to mitigate financial risks associated with unsuccessful outcomes.Meanwhile, Moderna is leveraging Nanexa's expertise in long-acting formulations to enhance injectable therapy delivery systems. This collaboration is indicative of a broader industry trend focused on optimizing drug delivery technologies to boost efficacy and patient compliance.Operational restructuring is also evident as Pfizer implements cost-cutting measures, including layoffs in Switzerland, as part of broader strategic initiatives to optimize operations amid rising R&D costs and pricing pressures. Simultaneously, Chris Boulton's transition from Amgen to Prolynx underscores the fluid movement of talent within the industry—a reflection of ongoing strategic realignments.Regulatory landscapes are shifting as well. The FDA's approval of the first non-drug at-home treatment for depression marks an expansion into alternative therapeutic modalities beyond traditional pharmaceuticals. This wearable device offers adults with major depressive disorder a novel treatment option, integrating technology into mental health care—a promising addition to holistic treatment strategies.In another significant regulatory update, Teva Pharmaceuticals agreed to delist numerous patents from the FDA's Orange Book following an FTC ruling. This move is anticipated to foster increased generic competition and potentially lower medication costs for conditions like asthma and diabetes—a critical shift towards greater market accessibility.The FDA has also finalized guidance on promotional materials for biologics and biosimilars, standardizing advertising practices to ensure accurate representation of these products' efficacy and safety profiles amidst an expanding biologics market.Moreover, the FDA has launched its Commissioner's National Priority Voucher Pilot Review Program to expedite critical drug approvals. The first beneficiary under this program was USAntibiotics with Augmentin XR, signaling a potential shift towards more rapid access to essential medications.On the international policy front, recent developments between the UK and US have led to reductions in medicine rebate rates within the UK. This adjustment could lead to increased spending on new medicines, indicating more favorable conditions for pharmaceutical Support the show

In today's episode of Every Day Is Saturday, Sam Crowley breaks down the life-changing power of “one more rep.” Whether you're in the gym, rebuilding your confidence, growing your faith, or fighting for a dream that feels out of reach, the breakthrough never comes from the first easy steps — it comes from the rep you don't want to do. The rep that burns. The rep no one sees. The rep that defines your character. Sam shares a raw, real story from his Wolverine comeback workout and explains why that final rep becomes the moment where your identity shifts and momentum returns. You'll learn how the “one more rep mindset” applies to fitness, business, relationships, and personal transformation — and why this simple discipline separates people who stay stuck from people who change their entire life. If you need motivation, clarity, or a push to get back on track, this episode will light a fire under you. Listen now and discover the small action that leads to massive breakthroughs.

More resources? ----------------------- Watch Full Episodes in my YouTube channel! https://youtube.com/@drtjahn ---------------------- Get Your Free Copy of my book, "Podiatry Profits Book: Crafting A Seven-Figure Lifestyle Practice" to grow your podiatry practice. You just cover the shipping: https://www.podiatryprofitsbook.com ---------------------- Do you want to build your dream private practice without the hassles of insurance networks? Then schedule a FREE 45-min Strategy Session with me. We will dive to look at your current practice and I will provide you with a crystal game plan for you: https://drtjahn.com/the-profit-accelerator-session/ ---------------------- I've created this EXCLUSIVE Private Facebook Group community of like-minded podiatrists who are coming together to build their DREAM PRIVATE PRACTICE, and FREE to join!! https://www.facebook.com/groups/podiatryprofits

This episode of the Physics World Weekly podcast features a lively discussion about our Top 10 Breakthroughs of 2025, which include important research in quantum sensing, planetary science, medical physics, 2D materials and more. Physics World editors explain why we have made our selections and look at the broader implications of this impressive body of research. The top 10 serves as the shortlist for the Physics World Breakthrough of the Year award, the winner of which will be announced on 18 December. Links to all the nominees, more about their research and the selection criteria can be found here. Physics World‘s coverage of the Breakthrough of the Year is supported by Reports on Progress in Physics, which offers unparalleled visibility for your ground-breaking research.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-dynamic landscape of these industries, recent advancements have underscored both the scientific ingenuity and strategic foresight shaping patient care today.Pfizer has unveiled promising clinical trial data for Tukysa, indicating its potential as a first-line maintenance therapy in HER2-positive breast cancer. This development suggests that Tukysa could delay disease progression, offering patients extended survival prospects and an improved quality of life. Additionally, Pfizer's recent licensing agreement with Yaopharma for YP05002—a small molecule GLP-1 agonist currently in Phase 1 trials aimed at obesity treatment—highlights their strategic push into the rapidly evolving obesity treatment market.Meanwhile, Fondazione Telethon, an Italian nonprofit organization, has achieved a significant milestone with FDA approval for Waskyra—the first gene therapy for Wiskott-Aldrich syndrome. This ex vivo gene therapy directly targets the genetic roots of this rare disease, shifting treatment from symptomatic management to addressing underlying causes. This approval is transformative not only for patients suffering from this condition but also for the broader field of gene therapies, heralding a new era in treating rare genetic disorders.On the strategic front, Eli Lilly's decision to establish a $6 billion active pharmaceutical ingredient manufacturing facility in Huntsville, Alabama, marks a pivotal investment in U.S. manufacturing capabilities. This site will be critical in producing APIs for small molecule and peptide medicines, a testament to Lilly's commitment to meeting growing therapeutic demands while bolstering domestic production resilience—a trend gaining momentum across the industry. In oncology, Eli Lilly's Jaypirca demonstrated an impressive reduction in disease progression during Phase 3 trials for chronic lymphocytic leukemia.Biocon's acquisition of Viatris' stake in their biosimilar subsidiary exemplifies the shifting dynamics within the biosimilars market. This move allows Biocon to consolidate its market position as biosimilars gain traction as cost-effective alternatives to branded biologics. Such strategic realignments are indicative of competitive maneuvering aimed at capturing greater market share and driving down healthcare costs.Roche has made strides with compelling results from its Phase 3 trial of giredestrant, an oral selective estrogen receptor degrader showing a 30% reduction in risk for invasive breast cancer recurrence or death. The significance of this development lies in offering an oral alternative to injectable treatments, potentially improving patient adherence and reshaping standard care protocols for hormone receptor-positive breast cancer. Furthermore, Roche has achieved another regulatory milestone with its monoclonal antibody Gazyvaro gaining EU approval for treating lupus nephritis following successful Phase 3 trials.Innovation continues unabated as Formation Bio forms a new subsidiary through a $605 million deal with Lynk Pharmaceuticals. By securing rights to a next-generation immunology asset, Formation Bio positions itself at the forefront of immunological research developments. Concurrently, BioNTech and Bristol Myers Squibb have reported positive results from Phase 2 trials of Pumitamig for triple-negative breast cancer—validating bispecific antibodies' efficacy within oncology.Collaborative efforts are also reshaping industry landscapes. Bora and Corealis have partnered to create an end-to-end contract development and manufacturing organization for oral solid dose drug development. This collaboration aims to streamline processes and provide scalable solutions through a single contracting source, reflecting a shift towards integrated service models that enhance efficiencySupport the show

 ROOT & REWIRE MEMBERSHIPCONNECT WITH LORNA:---> Instagram @lorna_bingeeatingcoach---> Tiktok @lorna_bingeeatingcoach

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of transformative events shaping the future of drug development, patient care, and global healthcare strategies.**Johnson & Johnson's Multiple Myeloma Advances** Johnson & Johnson has made significant strides in the treatment of multiple myeloma with their bispecific antibody, Tecvayli. In recent trials, Tecvayli has shown remarkable promise when used in combination therapies as a second-line treatment. This development is noteworthy as it could potentially challenge the dominance of CAR-T cell therapies like J&J's Carvykti by offering a more accessible and less complex alternative. For patients, this means potentially fewer logistical hurdles and a more straightforward therapeutic option, which could drastically improve patient care standards.**Regulatory Scrutiny on RSV Vaccines** Turning to regulatory news, the U.S. FDA has intensified its scrutiny of respiratory syncytial virus (RSV) vaccines developed by pharmaceutical giants such as Merck, AstraZeneca, and Sanofi for infants. This increased oversight follows reports linking some COVID-19 vaccines to adverse effects in children. The FDA's actions highlight the ongoing necessity for vigilant safety monitoring in vaccine development, especially for vulnerable populations like infants. This is a crucial step in ensuring that vaccines designed for our youngest population are both safe and effective.**Eli Lilly's Strategic Moves in Oncology and Beyond** Eli Lilly is making waves in oncology with its BTK inhibitor, Jaypirca. Despite strong phase 3 results that support its use as a first-line treatment for chronic lymphocytic leukemia (CLL), Lilly is focusing on its application as a second-line therapy. This strategic choice reflects an astute understanding of market dynamics and therapeutic niches where Jaypirca can provide substantial benefits despite competition from established first-line treatments. Additionally, Eli Lilly continues to leverage its financial success from its weight loss drug Tirzepatide to position itself as a central player in global pharmaceutical innovation. The company's strategic investments are likely to catalyze advancements across various therapeutic areas, reinforcing its role as a key contributor to medical breakthroughs.**Legislative Impact on Biopharma** In legislative news, the Biosecure Act's incorporation into the U.S. National Defense Authorization Act marks a strategic shift towards tightening regulations on Chinese biopharma entities regarding federal contracts by 2026. This move could have profound implications for international collaborations and competition within biotechnology innovation and drug development sectors. It signals a broader trend of increased scrutiny on foreign entities in sensitive industries like biopharmaceuticals.**China's Healthcare Transformation** China's healthcare landscape is undergoing significant transformation with the inclusion of drugs from companies like Pfizer, Lilly, and J&J into its first private insurance formulary. This development could enhance access to innovative medications within China, potentially improving health outcomes and influencing global pricing strategies in the pharmaceutical industry.**Gamida Cell's Milestone in Cell Therapies** In a major milestone for cell therapies, Gamida Cell has secured a second FDA approval for its stem cell therapy Omisirge. Initially approved to reduce infection risk during hematopoietic stem cell transplantations in blood cancer patients, Omisirge's expanded indication to treat severe aplastic anemia underscores the potential of cell therapies in addressing diverse hematologic conditions.**CSL Seqirus' New Facility in Australia** In Australia, CSL Seqirus has opened a $1 billion facility dedicated to producing cell-baSupport the show

2025 was the year love got messy...but it might be exactly what we needed to take our power back.This week, Andrea Knoche gets real about the year we just survived. From the wildest celebrity relationship highs and jaw-dropping breakups of 2025 to the behind-the-mic evolution of From Mrs. to Ms., Andrea unpacks what these stories say about our own love lives.It's a raw reflection on reinvention, self-worth, and choosing yourself as we head into 2026. If you're ready for intention over impulse, clarity over chaos, and relationships that actually align with your desires, this episode is your end-of-year reset.In this episode:1. What 2025's Biggest Celeb Breakups and Glow-Ups Reveal About Modern LoveFrom surprise engagements to long-term marriages ending, we unpack what these headline-making moments say about timing, chemistry, and the truth about relationship cycles in midlife and beyond.2. Why Reinvention Is the Real Love Story as We Head Into 2026We break down how to stop waiting for external validation, rewrite your own narrative, and choose relationships that meet your emotional standards — not societal expectations.3. How to Use the Lessons of This Year to Step Into Your Power Next YearReal talk on boundaries, emotional clarity, and self-sourced confidence so you can walk into 2026 with intention, alignment, and a whole new kind of main-character energy.And so much more...Looking for Andrea?Instagram: @from.mrs.2.msTikTok:@from.mrs.2.msWebsite: www.frommrs2ms.comEmail: Andrea@FromMrs2Ms.comYouTube: @FromMrs2Ms Hosted on Acast. See acast.com/privacy for more information.

Across industries, teams are solving massive, complex challenges — but too often, those breakthroughs stay hidden inside their organizations. The IISE Innovation Cup, sponsored by the University of Tennessee Knoxville, changes that. It gives teams a global stage to showcase measurable results, real-world impact, and the power of industrial and systems engineering in action.In this episode of Problem Solved, we take you inside the Innovation Cup- what it is, why it matters, and what great innovation truly looks like.You'll hear from: • Tom Mazzone, Innovation Cup committee member, on why the Cup exists and how it elevates ISE work • Aniket Ramekar (Mayo Clinic), on the digital door-sign project that transformed clinical workflows • Rishabh Bhandawat (Smurfit WestRock), on optimizing spare-parts inventory • Bill Harrington, Innovation Cup committee member, on the criteria that separate a good project from a great oneWhether you work in healthcare, manufacturing, supply chain, aerospace, or continuous improvement, this episode will inspire you to look at your systems in a new way — and maybe even submit your own project.Submissions for the IISE Innovation Cup are now open.Learn more about the IISE Innovation Cup.Bill Harrington's unedited interview on IISE Innovation Cup judging criteria:https://youtu.be/fHlwnq74HqwMake sure you subscribe to Problem Solved so you never miss an episode!Learn more about The Institute of Industrial and Systems Engineers (IISE)Problem Solved on LinkedInProblem Solved on YouTubeProblem Solved on InstagramProblem Solved on TikTokProblem Solved Executive Producer: Elizabeth GrimesInterested in contributing to the podcast or sponsoring an episode? Email egrimes@iise.org

Message from our Sponsor: Looking for top-tier talent to join your team? Call The Allred Group for your elevator recruiting needs! With a deep network and unmatched industry expertise, we quickly connect you with skilled professionals who are ready to elevate your team.  Let us handle the hiring process, so you can focus on growing your business with the best in the industry. Reach out today, and let us help you take your business to new heights!To contact us go to: http://allredgroup.comIntro: Today's episode brings together the experiences of three women as they reflect on what it means to build a career in a male-dominated trade. Featuring Erin Scott with ATIS, Emerald Kuhns with NAESA International, and Shannon Drezek with the IUEC. They share the challenges they've faced, the programs and support systems that made a difference, and the courage it takes to speak up in spaces where women are still underrepresented. They also discuss the progress happening across the industry, from growing female participation to shifting workplace culture, and the barriers that still need to be addressed for the next generation.

Hour 1 of https://RushToReason.com opens with intensity and purpose as Dr. Scott Faulkner (https://castlerockregenerativehealth.com), filling in for John Rush, teams up with expert biohacker Jeremy Sova to deliver a powerful Health and Wellness Wednesday. Together, they challenge listeners to rethink everything they believe about aging, medicine, and longevity. Why is traditional healthcare failing millions—and what happens when you step outside the system to measure, optimize, and actually reverse the damage inside your body? From cutting-edge biomarkers and rapamycin protocols to hyperbaric oxygen, VO₂ max testing, and personalized data tools like the Oura Ring, Dr. Scott and Jeremy reveal a roadmap to becoming biologically younger—no matter your age or past habits. Can a former smoker achieve elite VO₂ max numbers? Could early detection tools catch cancer before symptoms appear? And what if the secret to living longer isn't more medication, but more information? Websites mentioned: https://castlerockregenerativehealth.com/ https://ouraring.com/ https://www.questdiagnostics.com/ https://www.cancerchecklabs.com/ HOUR 2 Hour 2 explodes with cutting-edge health insight as biohacker Jeremy Sova and Dr. Scott plunge into the hidden world of mitochondria, omega-3 optimization, stem cells, and advanced cardiac imaging. Why are so many people walking around with perfect calcium scores while soft plaque silently builds toward disaster? And could AI-powered CT angiograms—with Clearly technology—be the tool that uncovers the truth before it's too late? A heart-stopping live call from Rick, whose scan revealed a 98% blockage despite minimal symptoms, becomes a turning point showcasing just how radically this new technology can save lives. From personalized biomarkers to the failures of traditional medicine, the hour exposes the cracks in America's healthcare system and reveals why functional and regenerative medicine are rising fast. Dr. Scott's raw backstory—his battle against bureaucracy, burnout, and a system that rewards silence over truth—adds emotional depth and a powerful challenge: what happens when a doctor refuses to be a coward? HOUR 3 Hour 3 of Rush to Reason ignites with Dr. Scott and expert biohacker Jeremy Sova diving into some of the most groundbreaking advances in modern regenerative medicine. What if stem cells could help a paralyzed man walk again… or reverse early Alzheimer's? What if your body could regrow neural networks once believed to be permanently damaged? And what if aging itself—telomere shortening, senescent “zombie cells,” mitochondrial decline—could be slowed, halted, or even reversed? Dr. Scott takes listeners behind the scenes of A4M, the world's largest anti-aging medical summit, where he is a featured stem-cell speaker teaching thousands of physicians global best practices. Together, he and Jeremy unpack cutting-edge research from Japan, Germany, and Israel on stem cells, plasmapheresis, and hyperbaric oxygen therapy—modalities that may radically expand healthspan and quality of life. Along the way, Dr. Scott exposes why so much breakthrough science happens outside the United States and challenges listeners to rethink a medical system built on disease management rather than healing. This is a riveting episode of Rush To Reason for anyone curious about longevity, brain restoration, or the future of medicine—and it just might change the way you think about aging forever.

From breakthrough AI diagnostics to personalized immunotherapy treatments, cancer care is undergoing a revolution that's already saving lives.Dr. Ross Levine, Chief Scientific Officer at Memorial Sloan Kettering, shares how new technologies are helping doctors detect cancer earlier, treat it more effectively, and transform what was once untreatable into manageable conditions. Whether you're navigating cancer personally or professionally, this conversation offers crucial insights into the future of medicine and why there's unprecedented hope in cancer treatment today.You can find Ross at: Website | Episode TranscriptIf you LOVED this episode, don't miss a single conversation in our Future of Medicine series, airing every Monday through December. Follow Good Life Project wherever you listen to podcasts to catch them all.Check out our offerings & partners: Join My New Writing Project: Awake at the WheelVisit Our Sponsor Page For Great Resources & Discount Codes Hosted on Acast. See acast.com/privacy for more information.

Today one of the most vulnerable, challenging, and meaningful videos I've ever made... A deep dive into how you can experience breakthroughs in your running and life.   This episode is different than usual. It's a presentation I recorded while trying to run a Sub 3 hour marathon and let's just say, not everything always goes exactly according to plan. It's how we respond to these situations that matters most.   This episode has many visual examples that are better experienced while watching the video, vs listening to it. It could probabably still work as a podcast too.   After about 27 minutes something unexpected happens on this run. You can either listen to it, or fast forward 6 minutes to 33 minutes, for a detailed summary and conclusions.   Watch this full video on YouTube: https://youtu.be/_Hz1zJblJ5A      CHAPTERS: 0:00 How to Run a Breakthrough  1:26 Running Advice from Eliud Kipchoge, the GOAT 1:59 What is a Running Breakthrough 4:33 Real Examples of Running Breakthroughs 5:50 The Most Common Challenges Runners Face 7:39 Understanding Healthy Heart Rate Training 9:22 5 Ways to Calculate Your Easy & Hard Zones 10:50 How to Start Heart Rate Training 11:12 The 3 Training Dials You Must Master 11:52 Finding the Right Weekly Running Volume For You 13:54 Sample Training Week (Breakdown & Structure) 16:08 My Exact Running Watch Settings 17:06 What Running Flow Is And How to Access It 20:21 The Power of Living an Unhurried Life 21:44 How Journaling Can Improve Your Running Performance 22:37 How to Handle Running Frustrations 23:21 4 Drills to Help You Run with Ease  26:30 How to Finish Strong   32:03 Crossing the Finish Line 32:29 Marathon Recap, lessons learned 34:07 How to Transform Your Running and Life      LINKS AND TOOLS MENTIONED: ► Buy my book Running Breakthroughs and get amazing book bonuses: https://florisgierman.com  ► Buy my book on Amazon Worldwide - https://geni.us/running-breakthroughs  ► HR Training Zone Calculator: https://bit.ly/hr-calculator ► MAF 180 formula: https://philmaffetone.com/180-formula/ ► Talk Test: https://youtu.be/AoB2AMUq8Wg ► Lactate Testing: https://bit.ly/3WAbI5z ► Flow Rope: https://innerunnerstore.myshopify.com/ ► Path Projects: https://pathprojects.com/ ► Join Our Personal Best Running Coaching Program: https://www.pbprogram.com     PODCASTS SHOWN: ► Kipchoge's Advice to Race Faster, For Non-Elites: https://youtu.be/7E6TNeoOC3Y ► Courtney Dauwalter's Advice to Improve Your Running: https://youtu.be/OTgwIEAN3B4 ► Kilian Jornet's Advice to Race Faster: https://youtu.be/OJZO-t6O5Bk ► Lawrence van Lingen: Unstuck Your Running: https://youtu.be/QSv1bEWjepE ► Heido Moreno From Struggling Runner to Running Success: https://youtu.be/f5DBINpRv78 ► Wiliam Barth Reveals the Truth About Low Heart Rate Training: https://youtu.be/SrI6GmzAAy4 ► Dr. Phil Maffetone Interview by Floris Gierman about Heart Rate Training, Nutrition and Recovery: https://youtu.be/_TPrenWWK9U ► How Ayako Ran Her Best Times Over 50: https://youtu.be/DI0cOUQRU1I  ► Daniel Edwards - What If You Could Shave 1 Hour Off Your Marathon Time? - https://youtu.be/n-Sr9whnctc      YOU CAN FIND ME, COACH FLORIS GIERMAN HERE:  ► My Personal Best Running Coaching Program: https://www.pbprogram.com/  ► YouTube: https://www.youtube.com/florisgierman ► Strava: https://www.strava.com/athletes/1329785  ► Instagram: https://www.instagram.com/florisgierman  ► Extramilest: https://extramilest.com/  ► Path Projects: https://pathprojects.com/flo ► Podcast: https://extramilest.com/podcast/    Affiliate Disclosure: I may earn commissions if you purchase items via my affiliate links. "As an affiliate I earn from qualifying purchases." Affiliate links do not increase cost to you. Also, you do not need to use these links. You can also search for these same items in Amazon or on any search engine/shopping site of your choice and buy/research them that way.     ABOUT THE EXTRAMILEST SHOW: A podcast and YouTube channel where host Floris Gierman interviews world class athletes, coaches and health experts on the topic of how to become a stronger, healthier and happier athlete.     More info about our Personal Best Running Coaching Program can be found at https://www.pbprogram.com.      SUBSCRIBE and hit the bell to see new videos: https://bit.ly/Flo-YT  

In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas in modern medicine: using one-time gene editing to permanently lower cholesterol and prevent heart disease.Dr. Kathiresan shares his journey from immigrant upbringing to Harvard cardiologist, genetic researcher, biotech founder, and now leader inside a global pharmaceutical company. The conversation explores how human genetics, CRISPR base editing, lipid nanoparticle delivery, and asymmetric learning converged to create a potential lifelong solution to cardiovascular disease.They also dive deep into the ethics of gene editing, global access and pricing, early intervention versus chronic care, FDA regulatory challenges, and what the Verve–Lilly acquisition means for the future of cardiometabolic medicine.This episode is a must-listen for anyone interested in biotech innovation, gene therapy, cardiovascular disease, and the future of preventive medicine. 00:00 Introduction and Guest Welcome01:16 Sekar Kathiresan's Early Life and Education03:19 Founding Verve and Transition to Entrepreneurship05:35 The Science Behind Verve's Mission10:27 Challenges and Breakthroughs in Gene Editing20:05 Regulatory Hurdles and First Human Trials25:11 Ethical Considerations in Gene Editing27:06 Introduction to Drug Delivery and Ethical Considerations27:51 Historical Context and Pioneers in Medical Procedures28:35 Commercial and Ethical Challenges in Medicine29:32 Innovations in Cardiovascular Treatments32:49 The Role of Gene Editing in Long-term Health37:55 Strategic Partnerships and Industry Insights45:08 Reflections on the US Medical Ecosystem48:54 Conclusion and Future Outlook Keep up with Sekar Kathiresan;LinkedIn: https://www.linkedin.com/in/sekar-sek-kathiresan-3501846/Website: https://www.lilly.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/ 

In this reflective year-end episode of the Red Delta Project Podcast, Matt dives into the three biggest lessons that transformed his training, thinking, and overall well-being in 2025. These aren't quick tips or simple fitness hacks, these are the deeper, paradigm-shifting insights that came from writing Beautiful Strength, exploring the true nature of recovery, reshaping his environment, and understanding the power of emotional conditioning.You'll learn why needing lots of recovery can be a red flag rather than a badge of honor, how curating your physical and digital environment can drastically improve your habits without relying on willpower, and why emotional conditioning may be the next frontier in building a stronger, healthier, more resilient version of yourself.If you're ready to break free of the diet and exercise rat race and step into 2026 with more clarity, confidence, and control—this is an episode you won't want to miss.Plus, don't forget to follow the ongoing RDP Fitness Advent Calendar, with daily videos from December 1–24 designed to make fitness easier and far more effective.

This week is not business as usual. We're entering December under a long void moon, heading straight into a Gemini Full Moon, a Sun–Nodes square, Mars trine Chiron, and a Mercury–Jupiter breakthrough transit that closes one chapter and opens another.If you've been waiting for clarity, movement, or a sign — this is it.✨ WATCH + STAY AHEAD OF:Longest void moon  (don't start anything new)Full Moon in Gemini at 13° (what's revealed + released)Sun square Nodes (karmic turning point)Mars trine Chiron (healing → power)Mercury trine Jupiter (third + final activation)What to do / what not to do this week

Bill rambles about breakthroughs, a bike ride, and the valley. (00:00) - Thursday Afternoon Podcast (30:35) - Thursday Afternoon Throwback 12-4-17 - Bill rambles about la-z-boys, college playoffs, and nosy neighbors. (01:54:06) - Anything Better Podcast - NFL Week 14 Preview with Paul Virzi. Bill went 3-1 and Paul went 2-2. They talk about the weeks games as well as crazy people in public, the scene in New Orleans, and Lane Kiffin's move. SimpliSafe: This month only, take 50% off any new system. This is one of the best prices you will ever see for SimpliSafe. Go to http://www.SimpliSafe.com/BURR Helix: Take the Helix Sleep Quiz and find your perfect mattress in under two minutes. Go to http://www.HelixSleep.com/burr for 20% off sitewide.

80% of a fish's diet is underwater, which means nymphing is a crazy effective way to put fish in the net. So, this week on Untangled, Spencer and Alex share everything they learned while filming their Nymphing Master Class. From insight on why fly pattern doesn't matter, to tips on picking the right strike indicator, you'll leave this episode ready to put all these tips into practice out on the water.  LINKS FROM THE SHOW Join the VFC Online Community - CHECK IT OUT QUESTIONS FOR THE SHOW - SUBMIT HERE #LIVEREELLIFE MOMENT - SUBMIT HERE VIDEO - Nymphing Master Class - CHECK IT OUT    

As we wrap up 2025, Arash walks us through how to reinvent yourself before December 31st. Dive into a real and raw conversation, because who you are on the 31st will determine the momentum you carry into 2026. In this action-focused episode, Arash unpacks the rules of 30-day transformation: why your old self has to die, the importance of setting a clear intention, and how to spot the excuses keeping you stuck. He breaks down how to define the person you're becoming, shares a day-by-day example of staying accountable, and gives you a right-now, actionable step to begin your shift. If you're ready to become the biggest and boldest version of yourself in just 30 days, this is the episode you don't want to miss!Key Points From This Episode:The topic for today's podcast: reinventing yourself in just 30 days.Arash unpacks the rules for transforming in 30 days.Why you need to let the old self die.Breakthroughs don't happen randomly; you have to set an intention.He breaks down actionable steps to get listeners started on their transformation.Mykie shares two reformed behaviors that changed her life.Identifying the top four excuses and some examples of what excuses could be. Defining who you will become: one habit, one standard, three goal-achieving actions, and a transformed belief.Arash details a day-to-day example of maintaining accountability in your transformation.Stacking evidence, one day at a time.The right-now action step for today's episode.Links Mentioned in Today's Episode:Schedule a call with Monica Da Maren EmailMonica Da Maren on InstagramVoss Coaching CoVoss Coaching Co on LinkedIn Voss Coaching Co on InstagramVoss Coaching Co on FacebookMykie Stiller on LinkedInMykie Stiller on Instagram Arash Vossoughi on LinkedInArash Vossoughi on YouTube

In this groundbreaking episode of Unleashing Intuition Secrets, Michael Jaco sits down with David Schmidt, the visionary inventor, CEO, and founder of LifeWave, for one of the most revealing conversations ever captured about the future of human energy, healing, and technological evolution. With more than 200 patents worldwide, Schmidt opens up about the extraordinary breakthroughs showcased at the recent LifeWave convention in Anaheim and the divine inspiration behind his life's work. He shares how biblical codes, intuition, and advanced science have guided his research into phototherapy, stem cell activation, and regenerative technology. Michael and David explore the origins of LifeWave—the intense three-year research journey that led to wireless phototherapy communication with the body—and how innovations like the X39® stem cell activation patch emerged after a decade of scientific development. Schmidt also discusses his early engineering ventures, designing hydrogen production systems, multi-fuel turbines, and advanced propulsion technologies for military and commercial use. The conversation then moves into LifeWave's newest and most ambitious advancements, including: • The X2O water system, designed to transform water quality and supply • Next-generation energy solutions capable of powering homes • Breakthroughs in human energy production • Plans for global expansion, celebrity partnerships, and a fully evolved future for LifeWave Michael and David also highlight the incredible impact users are experiencing with LifeWave patches, the company's newly enhanced compensation plan, and how these technologies will shape the health and wellness landscape worldwide. This is a must-listen episode for anyone interested in cutting-edge healing technologies, human potential, and the powerful intersection of science and spirituality. Explore LifeWave with Michael Jaco: https://www.lifewavemichaeljaco.com Learn more about LifeWave technology and product insights: https://liveyounger.com/ Stay in the love vibrations as innovation, intuition, and healing come together to shape the future. ✨

How to Heal Fertility by Starting With Gut Health What if fertility struggles aren't just about age, hormones, or luck—but about the foundation of your health: your gut? In this episode, I sit down with fertility coach and podcast host Monica Cox to break down the often-missed connection between gut health, inflammation, and reproductive challenges. Monica shares her eight-year journey through IVF, unexplained infertility, miscarriage, and the moment everything shifted: addressing food intolerances, calming her immune system, and rebuilding her health from the inside out. You'll learn why conventional fertility advice skips critical root-cause issues, how gut and cellular health affect egg quality and inflammation, and why intuition is a powerful tool in the healing process. If you're navigating fertility struggles—or supporting someone who is—this episode offers clarity, hope, and truly actionable next steps. What You'll Learn Why gut health plays a major role in fertility The truth about egg quality and inflammation What autoimmune markers can reveal The diet shifts that changed Monica's journey How stress, grief, and emotional overload impact the body Practical gut-support strategies you can start today The role of joy and intuition in healing Chapters 00:00 – Welcome Monica Cox 01:10 – Why Gut Health Matters 02:34 – Monica's IVF Journey 05:41 – Egg Quality Myths 07:28 – Autoimmune Testing & Inflammation 09:01 – Diet Changes and Breakthroughs 12:00 – Emotional Stress & Fertility 14:02 – Moving Forward After Miscarriage 16:00 – Defining Your Own Journey 19:10 – Helping Women Over 40 21:22 – Practical Gut Health Tips 24:11 – Intuition in Healing 25:21 – Importance of Joy 26:37 – Where to Find Monica Cox 27:13 – Final Thoughts & Encouragement Guest Links Monica Cox — "Finding Fertility" Podcast, website, and DMs for personalized guidance.

Welcome back to another episode of Impact Theory with Tom Bilyeu! In today's episode, Tom is joined by Mason for a wide-ranging conversation just before the Thanksgiving holiday. Together, they dive deep into timely topics, exploring why the Russia-Ukraine conflict should matter to everyday Americans, the daunting prospects of America's growing national debt, and the ripple effects of foreign policy on domestic life. Tom breaks down the nuances of global alliances, the dangers and opportunities posed by rapidly advancing AI, and the ever-controversial interplay between capitalism and government intervention. The discussion also examines the limits of personal impact on massive systemic issues, the importance of meaning over money, and the real-world implications of social and political upheaval—offering insights, hard truths, and a dose of hope for listeners. Whether it's handling the economics of war, the prospects of AI superintelligence, or what keeps Tom motivated beyond financial success, this episode serves up thought-provoking commentary and practical wisdom. So grab your coffee, settle in, and get ready for a candid, insightful journey into the issues shaping our world—only on Impact Theory. Thank you to today's Sponsors: Linkedin: Post your job free at https://linkedin.com/impacttheory HomeServe: Help protect your home systems – and your wallet – with HomeServe against covered repairs. Plans start at just $4.99 a month at https://homeserve.com True Classic: Upgrade your wardrobe at https://trueclassic.com/impact Incogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impact CashApp: Download Cash App Today: https://capl.onelink.me/vFut/v6nymgjl #CashAppPod Business Wars: Follow Business Wars on the Wondery App or wherever you get your podcasts. Shopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impact AirDoctor: Up to $300 off with code IMPACT at https://airdoctorpro.com Learn more about your ad choices. Visit megaphone.fm/adchoices